Masimo (NASDAQ:MASI) Releases FY 2024 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 3.800-4.000 for the period, compared to the consensus estimate of 3.620. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.1 billion. Masimo also updated its FY24 guidance to $3.80-4.00 EPS.

Masimo Stock Up 0.2 %

Shares of MASI stock traded up $0.30 on Friday, reaching $128.24. 227,488 shares of the company were exchanged, compared to its average volume of 674,921. The company has a market cap of $6.82 billion, a price-to-earnings ratio of 87.76 and a beta of 0.97. The company has a 50-day moving average of $118.82 and a 200-day moving average of $127.81. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.31 and a quick ratio of 1.31. Masimo has a one year low of $75.22 and a one year high of $153.93.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. The company had revenue of $496.30 million for the quarter, compared to analysts’ expectations of $493.92 million. Masimo had a net margin of 4.01% and a return on equity of 13.26%. The business’s revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.62 EPS. Analysts anticipate that Masimo will post 3.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus upgraded shares of Masimo from a hold rating to a buy rating and upped their target price for the stock from $148.00 to $170.00 in a report on Monday, April 15th. Needham & Company LLC restated a hold rating on shares of Masimo in a report on Wednesday. Finally, Piper Sandler upped their target price on shares of Masimo from $160.00 to $165.00 and gave the stock an overweight rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Masimo presently has an average rating of Moderate Buy and an average price target of $144.29.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.